Lo M Sosinski1, Christian Martin H1, Kerri A Neugebauer1, Lydia-Ann J Ghuneim1, Douglas V Guzior2, Alicia Castillo-Bahena3, Jenna Mielke4, Ryan Thomas5, Marc McClelland3, Doug Conrad4, Robert A Quinn6. 1. Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA. 2. Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA; Department of Microbiology and Molecular Genetics, Michigan State University, East Lansing, MI, USA. 3. Spectrum Health, Grand Rapids, MI, USA. 4. Department of Medicine, University of California San Diego, La Jolla, CA. 5. Department of Pediatrics and Human Development, Michigan State University, East Lansing, MI, USA. 6. Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, USA. Electronic address: quinnrob@msu.edu.
Abstract
BACKGROUND: Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy is showing promising efficacy for treatment of cystic fibrosis (CF) and is becoming more widely available since recent FDA approval. However, little is known about how these drugs will affect lung infections, which are the leading cause of morbidity and mortality among people with CF (pwCF). METHODS: We analyzed sputum microbiome and metabolome data from pwCF (n=24) before and after ETI therapy using 16S rRNA gene sequencing and untargeted metabolomics. RESULTS: The sputum microbiome diversity, particularly its evenness, was increased (p=0.036) and the microbiome profiles were different between individuals before and after therapy (PERMANOVA F=1.92, p=0.044). Despite these changes, the microbiomes remained more similar within an individual than across the sampled population. No specific microbial taxa differed in relative abundance before and after therapy, but the collective log-ratio of classic CF pathogens to anaerobes significantly decreased (p=0.013). The sputum metabolome also showed changes associated with ETI (PERMANOVA F=4.22, p=0.002) and was characterized by greater variation across subjects while on treatment. Changes in the metabolome were driven by a decrease in peptides, amino acids, and metabolites from the kynurenine pathway, which were associated with a decrease in CF pathogens. Metabolism of the three small molecules that make up ETI was extensive, including previously uncharacterized structural modifications. CONCLUSIONS: ETI therapy is associated with a changing microbiome and metabolome in airway mucus. This effect was stronger on sputum biochemistry, which may reflect changing niche space for microbial residency in lung mucus as the drug's effects take hold. FUNDING: This project was funded by a National Institute of Allergy and Infectious Disease Grant R01AI145925.
BACKGROUND: Elexacaftor-Tezacaftor-Ivacaftor (ETI) therapy is showing promising efficacy for treatment of cystic fibrosis (CF) and is becoming more widely available since recent FDA approval. However, little is known about how these drugs will affect lung infections, which are the leading cause of morbidity and mortality among people with CF (pwCF). METHODS: We analyzed sputum microbiome and metabolome data from pwCF (n=24) before and after ETI therapy using 16S rRNA gene sequencing and untargeted metabolomics. RESULTS: The sputum microbiome diversity, particularly its evenness, was increased (p=0.036) and the microbiome profiles were different between individuals before and after therapy (PERMANOVA F=1.92, p=0.044). Despite these changes, the microbiomes remained more similar within an individual than across the sampled population. No specific microbial taxa differed in relative abundance before and after therapy, but the collective log-ratio of classic CF pathogens to anaerobes significantly decreased (p=0.013). The sputum metabolome also showed changes associated with ETI (PERMANOVA F=4.22, p=0.002) and was characterized by greater variation across subjects while on treatment. Changes in the metabolome were driven by a decrease in peptides, amino acids, and metabolites from the kynurenine pathway, which were associated with a decrease in CF pathogens. Metabolism of the three small molecules that make up ETI was extensive, including previously uncharacterized structural modifications. CONCLUSIONS: ETI therapy is associated with a changing microbiome and metabolome in airway mucus. This effect was stronger on sputum biochemistry, which may reflect changing niche space for microbial residency in lung mucus as the drug's effects take hold. FUNDING: This project was funded by a National Institute of Allergy and Infectious Disease Grant R01AI145925.
Authors: Kai Dührkop; Markus Fleischauer; Marcus Ludwig; Alexander A Aksenov; Alexey V Melnik; Marvin Meusel; Pieter C Dorrestein; Juho Rousu; Sebastian Böcker Journal: Nat Methods Date: 2019-03-18 Impact factor: 28.547
Authors: J Kirk Harris; Brandie D Wagner; Edith T Zemanick; Charles E Robertson; Mark J Stevens; Sonya L Heltshe; Steven M Rowe; Scott D Sagel Journal: Ann Am Thorac Soc Date: 2020-02
Authors: Nicola J Ronan; Gisli G Einarsson; Maria Twomey; Denver Mooney; David Mullane; Muireann NiChroinin; Grace O'Callaghan; Fergus Shanahan; Desmond M Murphy; Owen J O'Connor; Cathy A Shortt; Michael M Tunney; Joseph A Eustace; Michael M Maher; J Stuart Elborn; Barry J Plant Journal: Chest Date: 2017-10-14 Impact factor: 9.410
Authors: Jiangchao Zhao; Patrick D Schloss; Linda M Kalikin; Lisa A Carmody; Bridget K Foster; Joseph F Petrosino; James D Cavalcoli; Donald R VanDevanter; Susan Murray; Jun Z Li; Vincent B Young; John J LiPuma Journal: Proc Natl Acad Sci U S A Date: 2012-03-26 Impact factor: 11.205
Authors: Harry G M Heijerman; Edward F McKone; Damian G Downey; Eva Van Braeckel; Steven M Rowe; Elizabeth Tullis; Marcus A Mall; John J Welter; Bonnie W Ramsey; Charlotte M McKee; Gautham Marigowda; Samuel M Moskowitz; David Waltz; Patrick R Sosnay; Christopher Simard; Neil Ahluwalia; Fengjuan Xuan; Yaohua Zhang; Jennifer L Taylor-Cousar; Karen S McCoy Journal: Lancet Date: 2019-10-31 Impact factor: 79.321
Authors: Maartje I Kristensen; Karin M de Winter-de Groot; Gitte Berkers; Mei Ling J N Chu; Kayleigh Arp; Sophie Ghijsen; Harry G M Heijerman; Hubertus G M Arets; Christof J Majoor; Hettie M Janssens; Renske van der Meer; Debby Bogaert; Cornelis K van der Ent Journal: J Pers Med Date: 2021-04-27
Authors: Anne H Neerincx; Katrine Whiteson; Joann L Phan; Paul Brinkman; Mahmoud I Abdel-Aziz; Els J M Weersink; Josje Altenburg; Christof J Majoor; Anke H Maitland-van der Zee; Lieuwe D J Bos Journal: ERJ Open Res Date: 2021-04-19
Authors: Francesca Saluzzo; Luca Riberi; Barbara Messore; Nicola Ivan Loré; Irene Esposito; Elisabetta Bignamini; Virginia De Rose Journal: Cells Date: 2022-04-06 Impact factor: 6.600
Authors: Lydia-Ann J Ghuneim; Ruma Raghuvanshi; Kerri A Neugebauer; Douglas V Guzior; Martin H Christian; Bella Schena; Jeremiah M Feiner; Alicia Castillo-Bahena; Jenna Mielke; Marc McClelland; Douglas Conrad; Isaac Klapper; Tianyu Zhang; Robert A Quinn Journal: ISME J Date: 2022-05-21 Impact factor: 11.217
Authors: Christina S Thornton; Nicole Acosta; Michael G Surette; Michael D Parkins Journal: J Pediatric Infect Dis Soc Date: 2022-09-07 Impact factor: 5.235